AtaiBeckley Inc. (ATAIN)
BMV
Closed
Nov 20, 2025
Day's Range
68.0052 wk Range
26.40Overview - ATAIN - AtaiBeckley Inc.
Key Statistics
Valuation
Enterprise Value
431.23B
Price / Book
‪5.71‬
EV / EBITDA
‪-242.42‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-3,796.52%‬
Return on Assets
‪-29.24%‬
Return on Equity
‪-100.77%‬
Ownership
Float
301.25M
Held by Insiders
‪3.69%‬
Held by Institutions
‪28.18%‬
Price stats
Beta
‪1.61‬
50-Day Avg
‪77.22‬
200-Day Avg
‪77.22‬
Peers - ATAIN - AtaiBeckley Inc.
Peer Comparison
Compared with companies in Biotechnology listed on BMV.
- ATAINBMVAtaiBeckley Inc.-24.96%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNBMVargenx SE American Depositary Receipt+4.58%52-week change33.44P/E (Trailing)‪32.26%‬Profit Margin
- BNTXNBMVBioNTech SE+4.53%52-week change1.65P/E (Trailing)‪-63.63%‬Profit Margin
- BMRNBMVBioMarin Pharmaceutical Inc.+4.43%52-week change178.64P/E (Trailing)‪2.14%‬Profit Margin
- AGIOBMVAgios Pharmaceuticals Inc.+0.00%52-week change5.17P/E (Trailing)‪88.25%‬Profit Margin
- ARWRBMVArrowhead Pharmaceuticals Inc.+0.00%52-week change-45455.00P/E (Trailing)‪-47.79%‬Profit Margin
- BEAMBMVBeam Therapeutics Inc.+28.41%52-week change-560.49P/E (Trailing)‪-55.44%‬Profit Margin
Profile Summary - ATAIN - AtaiBeckley Inc.
About
AtaiBeckley Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative psychedelic-based therapeutics and neuroplastogens to treat mental health disorders. The company was formed through the strategic combination of atai Life Sciences and Beckley Psytech Limited in November 2025. AtaiBeckley…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
